Aspirin-triggered proresolving mediators stimulate resolution in cancer
暂无分享,去创建一个
Sui Huang | D. Panigrahy | V. Sukhatme | C. Serhan | M. Kieran | A. Gartung | P. Norris | D. Bielenberg | Paul C. Norris | Molly M Gilligan | Megan L. Sulciner | M. Sulciner | Allison Gartung
[1] M. Bhasin,et al. Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin , 2018, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] B. Schmidt,et al. Anti-cancer and analgesic effects of resolvin D2 in oral squamous cell carcinoma , 2018, Neuropharmacology.
[3] N. Cook,et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials , 2018, The Lancet.
[4] C. Serhan,et al. Splenic leukocytes define the resolution of inflammation in heart failure , 2018, Science Signaling.
[5] Sui Huang,et al. Resolvins suppress tumor growth and enhance cancer therapy , 2018, The Journal of experimental medicine.
[6] K. Pienta,et al. Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone , 2017, The Journal of clinical investigation.
[7] O. Werz,et al. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity , 2018, Nature Communications.
[8] R. Melillo,et al. Formyl peptide receptor 1 suppresses gastric cancer angiogenesis and growth by exploiting inflammation resolution pathways , 2017, Oncoimmunology.
[9] I. Roitt,et al. Lipoxin A4 selectively programs the profile of M2 tumor‐associated macrophages which favour control of tumor progression , 2017, International journal of cancer.
[10] M. Perretti,et al. Resolvin D3 Is Dysregulated in Arthritis and Reduces Arthritic Inflammation , 2016, The Journal of Immunology.
[11] G. FitzGerald,et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells , 2016, OncoTarget.
[12] V. Steele,et al. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. , 2016, Seminars in oncology.
[13] Haoyu Kuang,et al. Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-κB activity. , 2016, Oncology reports.
[14] G. Casula,et al. Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer , 2015, British Journal of Cancer.
[15] M. Fiala,et al. Curcuminoids and ω-3 fatty acids with anti-oxidants potentiate cytotoxicity of natural killer cells against pancreatic ductal adenocarcinoma cells and inhibit interferon γ production , 2015, Front. Physiol..
[16] C. Serhan,et al. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. , 2014, American journal of physiology. Cell physiology.
[17] Charles N. Serhan,et al. Pro-resolving lipid mediators are leads for resolution physiology , 2014, Nature.
[18] M. Park,et al. Resolvin D1 inhibits TGF-β1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. , 2013, The international journal of biochemistry & cell biology.
[19] W. Harris,et al. n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial , 2013, Vascular medicine.
[20] P. Jakobsson,et al. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. , 2013, Carcinogenesis.
[21] C. Serhan,et al. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. , 2013, Chemistry & biology.
[22] C. Hudis,et al. Breast cancer risk reduction: no pain, no gain? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Charles N. Serhan,et al. Infection Regulates Pro-Resolving Mediators that Lower Antibiotic Requirements , 2012, Nature.
[24] Donald E Ingber,et al. Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. , 2012, The Journal of clinical investigation.
[25] Q. Mao-Ying,et al. Lipoxins and aspirin-triggered lipoxin alleviate bone cancer pain in association with suppressing expression of spinal proinflammatory cytokines , 2012, Journal of Neuroinflammation.
[26] A. Algra,et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.
[27] P. Nelson,et al. Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. , 2010, American journal of epidemiology.
[28] E. Fontaine,et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[29] D. Gilroy,et al. Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways , 2010, Proceedings of the National Academy of Sciences.
[30] R. Hannon,et al. Anti-Inflammatory Role of the Murine Formyl-Peptide Receptor 2: Ligand-Specific Effects on Leukocyte Responses and Experimental Inflammation , 2010, The Journal of Immunology.
[31] R. DuBois,et al. Eicosanoids and cancer , 2010, Nature Reviews Cancer.
[32] J. Cerhan,et al. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. , 2007, Journal of the National Cancer Institute.
[33] J. Uddin,et al. Resolvin D1 and Its Aspirin-triggered 17R Epimer , 2007, Journal of Biological Chemistry.
[34] Charles N. Serhan,et al. Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1 , 2007, The Journal of Immunology.
[35] O. Sansom,et al. Aspirin activates the NF-κB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer , 2006 .
[36] A. Sher,et al. Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1 , 2005, The Journal of experimental medicine.
[37] P. Ridker,et al. Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[38] R. DuBois,et al. Will an aspirin a day keep the endoscope away? , 2003, Gastroenterology.
[39] C. Serhan,et al. Resolvins , 2002, The Journal of Experimental Medicine.
[40] C. Serhan,et al. Resolvins , 2002, The Journal of experimental medicine.
[41] Michael J Thun,et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. , 2002, Journal of the National Cancer Institute.
[42] N. Arber,et al. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer , 1999, Current gastroenterology reports.
[43] L. Marnett,et al. Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.
[44] M. H. Lee,et al. Aspirin-Triggered Lipoxins (15-epi-LX) Are Generated by the Human Lung Adenocarcinoma Cell Line (A549)–Neutrophil Interactions and Are Potent Inhibitors of Cell Proliferation , 1996, Molecular medicine.
[45] C. Serhan,et al. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Vane,et al. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.
[47] L. Révész. Genetic Studies of the Relationship of Tumour–Host Cells: Effect of Tumour Cells killed by X-rays upon the Growth of Admixed Viable Cells , 1956, Nature.